A Pilot Study of Perillyl Alcohol in Pancreatic Cancer

Journal of Surgical Research

Volumn 147, Issue 2, 2008, Pages 194-199

  Matos, Jesus M ^a   Schmidt, C Max ^a,b   Thomas, Howard J ^a,b   Cummings, Oscar W ^a,b   Wiebke, Eric A ^a,b   Madura, James A ^a,b   Patrick Sr , Loehrer J ^a,b   Crowell, P L ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; Bak; pancreatic cancer; perillyl alcohol

Indexed keywords

CA 19-9 ANTIGEN; PERILLYL ALCOHOL; PROTEIN BAK;

ADULT; AGED; ANKLE INJURY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; FEMALE; HEADACHE; HUMAN; MALE; MICROSCOPY; NAUSEA; PANCREAS CANCER; PANCREAS SURGERY; PRIORITY JOURNAL; SMELLING DISORDER; TUMOR VOLUME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOTERPENES; PANCREAS; PANCREATIC NEOPLASMS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 43549111580     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.02.005     Document Type: Article

References (19)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics. 2003. CA Cancer J Clin 53 (2003) 5
2. Haag J.D., Lindstrom M.J., and Gould M.N. Limonene-induced regression of mammary carcinomas. Cancer Res 52 (1992) 4021
3. Haag J.D., and Gould M.N. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34 (1994) 477
4. Stayrook K.R., McKinzie J.H., Burke Y.D., et al. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18 (1997) 1655
5. Stark M.J., Burke Y.D., McKinzie J.H., et al. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 96 (1995) 15
6. Crowell P.L., Chang R.R., Ren Z.B., et al. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266 (1991) 17679
7. Crowell P.L., Ren Z., Lin S., et al. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47 (1994) 1405
8. Mills J.J., Chari R.S., Boyer I.J., et al. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55 (1995) 979
9. Ariazi E.A., Satomi Y., Ellis M.J., et al. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59 (1999) 1917
10. Azzoli C.G., Miller V.A., Ng K.K., et al. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51 (2003) 493
11. Bailey H.H., Levy D., Harris L.S., et al. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 85 (2002) 464
12. Bailey H.H., Wilding G., Tutsch K.D., et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 54 (2004) 368
13. Hudes G.R., Szarka C.E., Adams A., et al. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6 (2000) 3071
14. Liu G., Oettel K., Bailey H., et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 21 (2003) 367
15. Meadows S.M., Mulkerin D., Berlin J., et al. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 32 (2002) 125
16. Morgan-Meadows S., Dubey S., Gould M., et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 52 (2003) 361
17. Murren J.R., Pizzorno G., DiStasio S.A., et al. Phase I study of perillyl alcohol in patients with refractory malignancies. Cancer Biol Ther 1 (2002) 130
18. Ripple G.H., Gould M.N., Stewart J.A., et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4 (1998) 1159
19. Ripple G.H., Gould M.N., Arzoomanian R.Z., et al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6 (2000) 390